Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Liposome(II) + Ivonescimab in 2L SCLC
NCT06820762Phase 2Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Dalian Medical University
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan liposome injection, ivonescimab in small cell lung cancer (SCLC), sponsored by The Second Affiliated Hospital of Dalian Medical University. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
irinotecan liposome injectionivonescimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06820762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06820762.